FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Articles|June 23, 2021
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of June 23, 2021
Author(s)Sydney Jennings
Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.
Advertisement
How many people in the US have been vaccinated against COVID-19?
According to the US
• 53.6% of total US population has received at least 1 dose
• 45.4% of total US population is fully vaccinated
• 45.4% of total US population is fully vaccinated
The 5 states with the highest percentage of population fully vaccinated are:
1. Vermont: 64.5%
2. Maine: 60.3%
3. Massachusetts: 60.2%
4. Connecticut: 59.2%
5. Rhode Island: 57.5%
2. Maine: 60.3%
3. Massachusetts: 60.2%
4. Connecticut: 59.2%
5. Rhode Island: 57.5%
How many cases of COVID-19 have been confirmed in the US?
According to the
• 33 571 794 confirmed cases
• 602 670 deaths
• 602 670 deaths
The 5 states with the highest total confirmed cases are:
1. California: 3 811 097
2. Texas: 2 988 588
3. Florida: 2 354 416
4. New York: 2 112 649
5. Illinois: 1 389 892
2. Texas: 2 988 588
3. Florida: 2 354 416
4. New York: 2 112 649
5. Illinois: 1 389 892
Deaths: California has the most deaths due to COVID-19 with 63 409 reported fatalities, followed by New York with 53 639, and Texas with 52 155.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 179 324 611 confirmed cases, 3 885 405 deaths, and 2 722 185 355 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Elevated PSA in Primary Care: What to Consider Before Biopsy
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5